Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Neuralstem Begins Trial of Stem Cell Product to Treat Stroke Disability

publication date: Jan 15, 2014
US-based Neuralstem treated its first patient in a China stem cell trial that is testing NSI-566 as a treatment for motor deficits following a stroke. The Phase I/II trial is being conducted at BaYi Brain Hospital in Beijing. In the trial, Neuralstem's spinal-cord derived stem cells are being transplanted directly into the patient's brain near the stroke lesion. Neuralstem hopes the one-time treatment will rebuild the damaged neural circuitry. More details....

Stock Symbol: (NYSE: CUR)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital